Stephen V Liu Selected Research

Anaplastic Lymphoma Kinase

11/2022	Classical ALK G1202R resistance mutation was identified in a lung adenocarcinoma patient with rare LOC388942-ALK fusion after sequential treatment with ALK-TKIs and anlotinib: a case report.
10/2020	Novel ALK mutation with durable response to brigatinib-a case report.
3/2014	Emerging protein kinase inhibitors for non-small cell lung cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephen V Liu Research Topics

Disease

71	Neoplasms (Cancer) 04/2024 - 03/2010
37	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2024 - 03/2012
19	Lung Neoplasms (Lung Cancer) 04/2024 - 01/2013
17	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 02/2024 - 10/2016
11	Disease Progression 03/2024 - 05/2017
7	Prostatic Neoplasms (Prostate Cancer) 12/2017 - 09/2010
6	Carcinoma (Carcinomatosis) 12/2021 - 12/2012
4	Adenocarcinoma of Lung 12/2022 - 06/2021
4	Neoplasm Metastasis (Metastasis) 10/2021 - 12/2015
3	Thyroid Neoplasms (Thyroid Cancer) 11/2023 - 01/2017
3	Breast Neoplasms (Breast Cancer) 10/2023 - 03/2010
3	Head and Neck Neoplasms (Head and Neck Cancer) 01/2023 - 05/2017
3	Squamous Cell Carcinoma of Head and Neck 01/2023 - 05/2017
3	Brain Neoplasms (Brain Tumor) 12/2022 - 01/2018
3	COVID-19 01/2021 - 01/2020
2	Renal Cell Carcinoma (Grawitz Tumor) 04/2024 - 01/2017
2	Adenocarcinoma 02/2024 - 01/2018
2	Carcinogenesis 01/2024 - 01/2018
2	Central Nervous System Diseases (CNS Diseases) 01/2021 - 01/2017
2	Colorectal Neoplasms (Colorectal Cancer) 01/2021 - 01/2017
2	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 01/2016
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2020 - 12/2012
2	Circulating Neoplastic Cells 12/2017 - 12/2014
2	Melanoma (Melanoma, Malignant) 01/2017 - 01/2016
1	Bites and Stings (Sting) 02/2024
1	Glioblastoma (Glioblastoma Multiforme) 10/2023
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 10/2023
1	Neurologic Manifestations (Neurological Manifestations) 12/2022
1	Recurrent respiratory papillomatosis 11/2022
1	ST Elevation Myocardial Infarction 01/2022
1	Testicular Neoplasms (Testicular Cancer) 12/2021

Drug/Important Bio-Agent (IBA)

10	Immune Checkpoint InhibitorsIBA 03/2024 - 01/2019
9	Biomarkers (Surrogate Marker)IBA 03/2024 - 09/2015
9	atezolizumabIBA 02/2024 - 01/2018
8	Tyrosine Kinase InhibitorsIBA 10/2023 - 10/2017
8	pembrolizumabIBA 01/2023 - 05/2017
7	Carboplatin (JM8)FDA LinkGeneric 02/2024 - 12/2018
7	DNA (Deoxyribonucleic Acid)IBA 02/2024 - 12/2012
7	entrectinibIBA 05/2022 - 12/2015
6	Phosphotransferases (Kinase)IBA 04/2024 - 03/2014
6	PlatinumIBA 03/2024 - 05/2017
6	Etoposide (VP 16)FDA LinkGeneric 02/2024 - 12/2018
6	B7-H1 AntigenIBA 09/2022 - 01/2018
5	Gonadotropin-Releasing Hormone (GnRH)FDA Link 12/2017 - 09/2010
4	osimertinibIBA 10/2022 - 01/2021
4	Monoclonal AntibodiesIBA 11/2021 - 01/2018
4	Proteins (Proteins, Gene)FDA Link 12/2020 - 02/2015
3	LigandsIBA 03/2024 - 10/2019
3	Neuregulin-1 (Neuregulin 1)IBA 02/2024 - 01/2021
3	AfatinibIBA 01/2024 - 01/2021
3	pralsetinibIBA 11/2023 - 01/2021
3	RNA (Ribonucleic Acid)IBA 10/2023 - 08/2019
3	AntigensIBA 10/2023 - 10/2016
3	Immunoconjugates (Immunoconjugate)IBA 10/2023 - 11/2021
3	Anaplastic Lymphoma KinaseIBA 11/2022 - 03/2014
3	LHRH Receptors (Gonadotropin-Releasing Hormone Receptor)IBA 12/2017 - 06/2011
3	taxaneIBA 12/2017 - 03/2012
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 04/2024 - 12/2015
2	Programmed Cell Death 1 ReceptorIBA 03/2024 - 07/2021
2	alectinibIBA 11/2022 - 10/2020
2	agerafenibIBA 01/2022 - 01/2019
2	COVID-19 VaccinesIBA 05/2021 - 01/2021
2	VaccinesIBA 01/2021 - 01/2016
2	NivolumabIBA 01/2020 - 11/2019
2	CytokinesIBA 01/2019 - 01/2016
2	Cetuximab (Erbitux)FDA Link 01/2019 - 05/2017
2	rociletinibIBA 11/2018 - 03/2014
2	ErbB Receptors (EGF Receptor)IBA 11/2018 - 03/2014
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2018 - 12/2017
2	lysine(6)-doxorubicin LHRHIBA 12/2017 - 12/2014
1	zenocutuzumabIBA 02/2024
1	Interferon-gamma (Interferon, gamma)IBA 02/2024
1	Glutamine (L-Glutamine)FDA Link 02/2024
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 10/2023
1	Hormones (Hormone)IBA 01/2023
1	GenieIBA 01/2023
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 12/2022
1	sotorasibIBA 12/2022
1	anlotinibIBA 11/2022
1	erdafitinibIBA 11/2022
1	sintilimabIBA 01/2022
1	Thyroid Nuclear Factor 1IBA 01/2022
1	Circulating Tumor DNAIBA 01/2022
1	Pemetrexed (MTA)FDA Link 01/2022
1	TropomyosinIBA 01/2022
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 12/2021
1	Heat-Shock Proteins (Heat-Shock Protein)IBA 12/2021
1	SNX-5422IBA 12/2021
1	Paclitaxel (Taxol)FDA LinkGeneric 12/2021
1	tyrosine receptor (receptor, tyrosine)IBA 10/2021
1	Immunoglobulin G (IgG)IBA 07/2021
1	Epidermal Growth Factor (EGF)IBA 02/2021
1	Dasatinib (BMS 354825)FDA Link 01/2021

Therapy/Procedure

40	Therapeutics 03/2024 - 03/2010
20	Drug Therapy (Chemotherapy) 03/2024 - 03/2010
16	Immunotherapy 03/2024 - 01/2016
4	Castration 12/2017 - 09/2010
2	Aftercare (After-Treatment) 01/2024 - 01/2017
1	Time-to-Treatment 02/2024
1	Patient Readmission 01/2022